Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration to bring its target enrichment and sample library preparation kits to a novel automation platform developed by Miroculus, Inc.

“Our mission is to advance science and improve lives faster, together; and by bringing Twist’s high-quality library preparation and target enrichment workflows to the Miro Canvas system, we believe we can continue to streamline the experimental process and ultimately provide more efficient solutions for a wide range of clinical applications with maximum flexibility and reproducibility,” said Alejandro Tocigl, CEO and co-founder of Miroculus, Inc.

“Collaborating with Miroculus, an up-and-coming leader in the field of NGS workflow automation, signifies one more way in which we are bringing our versatile and clinically-efficient solutions to those researchers solving global challenges,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “While technology has truly revolutionized the way we identify diseases today, we have only seen the tip of the iceberg, and I believe there is much more to come as we not only interrogate genetic diseases but also determine optimal therapeutics through the use of medicinal and combinatorial chemistry. Pursuing these with the combined solutions of Miroculus and Twist has the potential to advance scientific progress towards these goals substantially.”

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to streamline experimental processes and provide more efficient solutions as a result of the collaboration, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.